DelveInsight Highlights Major Advances, Transformative Therapies, and 30+ Leading Players Wheeling the ALK-positive Non-Small Cell Lung Cancer Clinical Trial Pipeline Landscape

September 07 15:31 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 30+ Leading Players Wheeling the ALK-positive Non-Small Cell Lung Cancer Clinical Trial Pipeline Landscape

The ALK-positive Non-Small Cell Lung Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of ALK-positive Non-Small Cell Lung Cancer treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the ALK-positive Non-Small Cell Lung Cancer pipeline landscape and fostering the potential growth of ALK-positive Non-Small Cell Lung Cancer therapeutic advancements.

 

Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment.
  • The leading companies working in the ALK-positive Non-Small Cell Lung Cancer Market include GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutical, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.
  • Promising ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Alkotinib Capsules, Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, X-396 capsule, and others.
  • On June 2023, Pfizer announced a study of Phase 1 & 2 Clinical Trials for PF-06463922 and Crizotinib. Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non-small cell lung cancer patients.
  • On August 2023, Betta Pharmaceuticals Co. Ltd announced a study of Phase 2 Clinical Trials for X-396 capsule. The main purpose of the study is to evaluate safety and efficacy of X-396(Ensartinib) capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib. While exploring the relationship between biomarkers and drug efficacy and safety.

 

Request a sample and discover the recent advances in ALK-positive Non-Small Cell Lung Cancer Treatment Drugs @ ALK-positive Non-Small Cell Lung Cancer Pipeline Report

 

The ALK-positive Non-Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage ALK-positive Non-Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the ALK-positive Non-Small Cell Lung Cancer clinical trial landscape.

 

ALK-positive Non-Small Cell Lung Cancer Overview

ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it’s a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4).

 

Find out more about ALK-positive Non-Small Cell Lung Cancer Treatment Drugs @ Drugs for ALK-positive Non-Small Cell Lung Cancer Treatment

 

ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile

  • Ensartinib: Betta Pharmaceuticals/Xcovery
  • TQ-B3139 – Chia Tai Tianqing Pharmaceutical Group

 

ALK-positive Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The ALK-positive Non-Small Cell Lung Cancer companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.

 

Learn more about the emerging ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies @ ALK-positive Non-Small Cell Lung Cancer Clinical Trials Assessment

 

Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • ALK-positive Non-Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Ariad Pharmaceutical, Takeda, Chia Tai Tianqing Pharmaceutical Group, Akeso, and others.
  • ALK-positive Non-Small Cell Lung Cancer Pipeline Therapies- Alkotinib Capsules, Ceritinib, Lortlatinib, PF-06463922, Crizotinib, Ribociclib, X-396 capsule, and others.

 

Dive deep into rich insights for new drugs for ALK-positive Non-Small Cell Lung Cancer Treatment, Visit @ ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. ALK-positive Non-Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. ALK-positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. ALK-positive Non-Small Cell Lung Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Ensartinib: Betta Pharmaceuticals/Xcovery
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Bintrafusp alfa: EMD Serono/GlaxoSmithKline/Merck
  14. Early Stage Products (Phase I)
  15. PLB1003: Beijing Pearl Biotechnology Limited Liability Company
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. ALK-positive Non-Small Cell Lung Cancer Key Companies
  21. ALK-positive Non-Small Cell Lung Cancer Key Products
  22. ALK-positive Non-Small Cell Lung Cancer- Unmet Needs
  23. ALK-positive Non-Small Cell Lung Cancer- Market Drivers and Barriers
  24. ALK-positive Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
  25. ALK-positive Non-Small Cell Lung Cancer Analyst Views
  26. ALK-positive Non-Small Cell Lung Cancer Key Companies
  27. Appendix

 

For further information on the ALK-positive Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to ALK-positive Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting